| Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins. | |
| | |
MedLine Citation:
|
PMID: 3134243 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Daily subcutaneous doses of luteinizing hormone-releasing hormone (LHRH) analogues are a well-established therapy for gonadotropin-dependent precocious puberty. Reports on intranasally administered analogues, however, are controversial. We studied the effect of intranasal D-Ser(TBU)6-LHRH(BUS) on growth rate, skeletal maturation, and urinary gonadotropins in five girls and one boy with central precocious puberty (CPP) who had been treated for 1.4-2.3 years (mean 1.9). Because of the potential antifertility effects of LHRH analogues, testicular histology was analysed in the boy. In the five children with accelerated growth, the bone age-related velocity of height gain decreased from 10.58 +/- 2.77 to 5.82 +/- 1.8 cm/year (means +/- SD, P less than 0.01), and the ratio of change in bone age to change in chronological age fell below 1. Basal luteinizing hormone (LH), and LHRH-stimulated LH and follicle stimulating-hormone, at pubertal levels before treatment, decreased significantly in all children, normalizing in four (P less than 0.04). During therapy, pituitary function was best controlled by urinary LH, which correlated with clinical data. After 13 months of therapy, testicular histology showed degenerated Sertoli cells, and absence of B- and Ap-spermatogonia and of primary spermatocytes in the boy. We conclude that: (1) Efficient long-term suppression of central precocious puberty--including accelerated growth and skeletal maturation--can be maintained by intranasal dosage of BUS. (2) Urinary LH reflects pituitary function and proves to be a reliable guide to adjustment of the LHRH-analogue dose regimen.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
J L Rime; U Zumsteg; A Blumberg; F Hadziselimovic; J Girard; R P Zurbrügg |
Related Documents
:
|
1655823 - Maintained reduction of uterine leiomyoma following addition of hormonal replacement th... 3519743 - Pulsatile luteinizing hormone releasing hormone treatment for induction of ovulation. r... 2771583 - Variations in prolactin secretion in hyper- and normoprolactinaemia with or without gal... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of pediatrics Volume: 147 ISSN: 0340-6199 ISO Abbreviation: Eur. J. Pediatr. Publication Date: 1988 Apr |
Date Detail:
|
Created Date: 1988-08-18 Completed Date: 1988-08-18 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7603873 Medline TA: Eur J Pediatr Country: GERMANY, WEST |
Other Details:
|
Languages: eng Pagination: 263-9 Citation Subset: IM |
Affiliation:
|
Wildermeth Children's Hospital, Biel, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Intranasal Atrophy Bone Development Buserelin / administration & dosage, adverse effects, therapeutic use* Child Child, Preschool Female Gonadotropins, Pituitary / urine* Humans Infant Male Puberty, Precocious / drug therapy*, pathology, urine Radioimmunoassay Testis / pathology |
| Chemical | |
Reg. No./Substance:
|
0/Gonadotropins, Pituitary; 57982-77-1/Buserelin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of CIN with the CO2 laser vaporization.
Next Document: Intravenous immune globulin in symptomatic paediatric human immunodeficiency virus infection.